Peptides and combination of peptides for use in immunotherapy against various tumors
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that selectively recognize cells which present a peptide consisting of the amino acid sequence of SLLNQPKAV (SEQ ID NO: 235),
wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MHC molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells,
wherein said cancer is selected from the group consisting of glioblastoma (GB), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), ovarian cancer (OC), melanoma (MEL), colorectal cancer (CRC), pancreatic cancer (PC), esophageal cancer (OSCAR), small cell lung cancer (SCLC), urinary bladder cancer (UBC), uterine cancer (UTC), breast cancer (BRCA), gallbladder cancer and cholangiocarcinoma (GBC CCC), acute myeloid leukemia (AML), and Non-Hodgkin lymphoma (NHL).
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , wherein the activated T cells are expanded in vitro.
6. The method of claim 1 , wherein the MHC molecule is a class I MHC molecule.
7. The method of claim 1 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.
8. The method of claim 7 , wherein the antigen presenting cell is a dendritic cell or a macrophage.
9. The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.
10. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.
11. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.
12. The method of claim 1 , wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SLLNQPKAV (SEQ ID NO: 235).
13. The method of claim 12 , wherein the immune response comprises a cytotoxic T cell response.
14. The method of claim 1 , wherein the cancer is glioblastoma (GB).
15. The method of claim 1 , wherein the cancer is non-small cell lung cancer (NSCLC).
16. The method of claim 1 , wherein the cancer is HCC.
17. The method of claim 1 , wherein the cancer is OC.
18. The method of claim 1 , wherein the cancer is MEL.
19. The method of claim 1 , wherein the cancer is CRC.
20. The method of claim 1 , wherein the cancer is BRCA.